SELLAS Life Sciences Group, Inc. (SLS) Misses Q1 EPS by 18c

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q1 EPS of ($0.47), $0.18 worse than the analyst estimate of ($0.29).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance